1. Volume 151, Issue 1, Pages 46-52 (October 2018)
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer 
Kathleen N. Moore, David M. O'Malley, Ignace Vergote, Lainie P. Martin, Antonio Gonzalez-Martin, Karim Malek, Michael J. Birrer 
Gynecologic Oncology 
Volume 151, Issue 1, Pages (October 2018)
DOI: /j.ygyno
Copyright © 2018 Elsevier Inc. Terms and Conditions

2. Fig. 1
Percent tumor change in target lesions by FRα expression. Data are presented from 15 patients as individuals with non-measurable disease were enrolled in the study. Asterix denotes patient still on study at time of final analyses. Dotted line in plots corresponds to 30% decrease in tumor size.
Gynecologic Oncology  , 46-52DOI: ( /j.ygyno )
Copyright © 2018 Elsevier Inc. Terms and Conditions

3. Fig. 2 Kaplan-Meier analysis of progression-free survival (PFS).
Gynecologic Oncology  , 46-52DOI: ( /j.ygyno )
Copyright © 2018 Elsevier Inc. Terms and Conditions